Public Release: 

Patients with moderate RA as likely to need joint surgery as those with high disease

Data support the use of lower disease activity cut-off points for more intensive treatments such as biologics

European League Against Rheumatism

Rome, Italy, 10 June 2015: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that patients with Rheumatoid Arthritis (RA) taking conventional DMARD therapy who have moderate disease activity have a similar risk of joint failure that requires surgery as those with high disease activity.

In some countries, additional treatment with a biological DMARD is based on a disease activity cut-off that excludes RA patients with moderate disease activity. These findings suggest it is not just the RA patients with high disease activity, but also those with moderate RA, who need more intensive treatment, to reduce their risk of needing joint surgery.

"It is well-established that sustained high disease activity in RA results in worse outcomes," said lead author Dr. Elena Nikiphorou of the Rheumatology Department, St Albans City Hospital, UK. "In reality, however, many treated RA patients remain in low or moderate disease activity states and their outcomes, especially in the long term, are less well studied," she added.

"Our data provide an argument for updating existing disease activity cut-off points to allow RA patients with moderate disease activity to receive a biological agent in addition to conventional DMARDs," Dr. Nikiphorou concluded.

In this study, orthopaedic surgery was used as a surrogate marker of joint destruction and failure in RA patients who remained at different disease activity levels over the first five years from the onset of their disease. Joint interventions were categorised into major (mainly large joint replacements), intermediate (e.g. synovectomies, joint fusions and excision arthroplasties of the wrist/hand, foot), or minor (mainly soft tissue surgery).

A total of 2,071 patients were recruited from the 'Early RA Study' and the 'Early RA Network'. Of these, 2,044 had at least two drug activity states (DAS) recorded between years 1 to 5: 21% were in remission, 15% in low DAS, 26% in low-moderate DAS, 21% in high-moderate DAS, and 18% in high DAS categories. Disease activity was evaluated by calculating the mean DAS28 score for each patient from year 1 (after treatment-onset) to year 5.

Using a statistical model that controlled for numerous factors including age at disease onset, gender, recruitment year, symptom duration, baseline rheumatoid factor, BMI, HAQ , erosions and haemoglobin, patients with low-moderate DAS, high-moderate DAS, and high DAS categories were all predictive of an increased risk of major joint surgery (p<0.005).

However, with respect to intermediate surgery, high-moderate DAS and high DAS predicted a higher risk than those patients with low-moderate DAS or low DAS (p=0.034 and p=0.001 respectively).

###

Abstract Number: OP0179

NOTES TO EDITORS:

For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress Press Office in Room 5B of Fiera Roma during EULAR 2015 or on:
Email: eularpressoffice@cohnwolfe.com
Onsite tel: +44 (0) 7738 890 799 / +44 (0) 20 7331 5442
Twitter: @EULAR_Press
Youtube: Eular Pressoffice

About EULAR

The European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.

EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.

With 45 scientific member societies, 35 People with Arthritis and Rheumatism in Europe (PARE) organisations, 19 health professionals associations and 21 corporate members, EULAR highlights the importance of combating rheumatic diseases through both medical means and patient care.

EULAR 2015 is set to be the biggest rheumatology event in Europe with around 14,000 scientists, physicians, allied health professionals and related audiences in attendance from more than 120 countries. Over the course of the congress there will be some 300 oral and just under 2,000 poster abstract presentations, more than 150 sessions, 400 lectures, 40 poster tours and 350 invited speakers

To find out more about the activities of EULAR, visit: http://www.eular.org

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.